These results argue against an elevated metabolism of Trp by IL4I1 in high-grade serous ovarian cancer patients and point towards IDO1/TDO as the dominant source of enhanced Trp metabolism. The gene discussed is TDO2; the disease is ovarian serous adenocarcinoma.